- Home
- FMS vs BBIO Comparison
FMS vs BBIO Comparison
Compare FMS & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMS | BBIO |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | Germany | United States |
| Employees | 108165 | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 12.7B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | FMS | BBIO |
|---|---|---|
| Price | $21.99 | $67.48 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 25 |
| Target Price | $30.00 | ★ $86.33 |
| AVG Volume (30 Days) | 754.1K | ★ 2.8M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | N/A | $89.45 |
| Revenue Next Year | $3.83 | $73.78 |
| P/E Ratio | $15.62 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $20.02 | $38.57 |
| 52 Week High | $29.07 | $84.94 |
Technical Indicators
Market Signals| Indicator | FMS | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 51.93 | 46.98 |
| Support Level | $21.76 | $62.37 |
| Resistance Level | $24.02 | $69.85 |
| Average True Range (ATR) | 0.32 | 2.77 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 70.52 | 46.43 |
Price Performance
Historical ComparisonAbout FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.